CDR132L

CDR132L is a synthetic antisense oligonucleotide (ASO) designed to selectively inhibit microRNA‐132‐3p (miR‐132), a molecule implicated in pathological cardiac remodeling and the progression of heart failure. By blocking miR‐132, CDR132L aims to prevent or reverse detrimental changes in heart structure and function, reduce abnormal growth of cardiomyocytes (hypertrophy), and improve both systolic and diastolic cardiac performance. The drug is water-soluble, formulated for intravenous or subcutaneous administration, and has demonstrated beneficial effects on left ventricular structure and function in preclinical models as well as safety and tolerability in early clinical studies. It is being developed primarily for post-myocardial infarction heart failure but is also under investigation for other forms of heart failure including those with preserved or mildly reduced ejection fraction[1][2][4][5][6][8].

Other names

CDR132LCDR-132LCDR 132LNN-6706NN6706NN 6706